A New Injectable Hydrogel Is Being Studied for Degenerative Disc Pain, and Early Results Are Encouraging
A feasibility study on a permanent gel implant for worn spinal discs showed pain and function gains held up at one year, offering a possible middle step between conservative care and surgery.
Key takeaways
- A feasibility study of an injectable hydrogel called Hydrafil, published in Pain Physician in January 2026, followed 60 patients with degenerative disc disease for a full year.
- Patients reported major gains in the Oswestry Disability Index and Numeric Pain Rating Scale that were still present at 12 months, though a larger pivotal trial is still needed.
- The outpatient procedure takes about 30 minutes under local anesthesia and does not require the disc space to be surgically opened.
- A small share of patients had gel migrate slightly outside the disc and needed a follow-up procedure to remove it, a reminder that this remains investigational.
Figures reported from the Pain Physician feasibility study of the Hydrafil injectable hydrogel implant, January 2026.
What researchers actually tested
Degenerative disc disease is one of the most common reasons people end up dealing with chronic low back pain, and by the time most adults reach their sixties, some wear and tear on the spinal discs is considered typical. The discs act like cushions between the vertebrae, and as they lose water content and structural integrity over the years, cracks and fissures can form that irritate nearby nerves and change how load is distributed across the spine.
A device called the Hydrafil System, made by ReGelTec, takes a different approach than many existing options. Instead of removing disc material or fusing vertebrae together, a clinician injects a liquefied hydrogel through a needle directly into the damaged disc. The gel is designed to fill cracks and fissures, then firm up as it cools, drawing water back into the disc to help restore some of its natural cushioning while still allowing normal spinal motion.
The feasibility study on the implant's safety and one-year results was published in the journal Pain Physician in January 2026. Researchers followed 60 chronic low back pain patients across three clinical sites in Canada and Colombia, treating 83 total discs at one or two levels per patient.
How patients did at one year
According to the published results, patients saw statistically and clinically meaningful improvement within the first month after the procedure, and those gains were largely sustained through the 12-month mark. Oswestry Disability Index scores, which measure how much back pain interferes with everyday activities like sitting, standing, and lifting, improved by more than 80 percent on average. Numeric Pain Rating Scale scores for back pain improved by more than 70 percent over the same period.
Every one of the 83 treated discs in the study received the implant successfully, with no procedural complications reported at the time of treatment or at discharge. Because the procedure is done under local anesthesia in an outpatient setting and takes roughly half an hour, researchers noted it could offer a lower-barrier option for patients who are not yet ready for, or are not candidates for, more invasive surgery such as spinal fusion.
Dr. Douglas Beall, a physician involved in evaluating the technology, was quoted describing the results as representing "an important milestone" for this kind of disc augmentation approach, while stressing that further evaluation is still underway before any broader approval decision.
The caveats that matter
This was a feasibility study, meaning its main purpose was to establish that the approach is workable and reasonably safe, not to prove it works better than existing treatments in a head-to-head comparison. Sixty patients is a modest sample, and the results have not yet been replicated in the larger, controlled trial that would typically support a full FDA approval.
Reporting on the study also noted a real safety signal worth flagging: about 8 percent of patients, or 5 of the 60, experienced increased pain or numbness after some of the injected gel migrated slightly beyond the disc space. In those cases, the displaced material was removed in a follow-up procedure. That is a useful reminder that even a minimally invasive, outpatient technique carries some risk and requires careful technique and monitoring.
ReGelTec has said it is now recruiting roughly 225 patients for a larger pivotal study intended to support a future FDA approval decision, building on breakthrough device designation the technology received in 2020. That means Hydrafil is still a research procedure at this stage rather than something widely available at spine clinics.
Where this could fit for Las Vegas patients
For people in the Las Vegas area managing disc-related back pain, the takeaway is not that a hydrogel injection is ready to book tomorrow, but that the pipeline of non-surgical and minimally invasive options for degenerative disc disease keeps growing. Approaches like this sit alongside other developing tools in the spine field, aiming to give patients and physicians more choices before major surgery becomes the only conversation.
As always with an emerging technology, the most useful next step for anyone dealing with persistent disc pain is a proper evaluation of what is actually driving the symptoms, since not every case of low back pain traces back to disc degeneration, and treatment plans work best when they are matched to an individual's specific findings and goals.
Where an Injectable Hydrogel Fits Among Disc Care Options
Degenerative disc disease is typically managed along a spectrum, from simple lifestyle changes up through surgery. Here is roughly where an investigational approach like this sits relative to more familiar options.
- Activity modification and physical therapy: Usually the first step for disc-related pain, focused on core strength, posture, and movement patterns that reduce load on the affected level.
- Oral medication and topical treatment: Anti-inflammatory or pain-relieving medications used short-term to manage flare-ups while other therapies take effect.
- Epidural steroid injections: A well-established option that targets inflammation around an irritated nerve root, often used for pain that radiates into the leg.
- Investigational disc augmentation (Hydrafil-type gel): An emerging, minimally invasive injection aimed at restoring disc structure directly, still in trial stages as of 2026.
- Minimally invasive decompression: Procedures that relieve pressure on a nerve without removing large amounts of bone or disc tissue.
- Spinal fusion surgery: A more involved surgical option generally reserved for cases where conservative and minimally invasive care has not resolved significant pain or instability.
Frequently Asked Questions
Is the Hydrafil hydrogel implant available for patients right now?
Not widely. It remains an investigational device studied in feasibility trials, and the company has said it is recruiting for a larger pivotal study to support a future approval decision. It is not a standard, broadly available treatment yet.
Does this study prove the gel works better than other treatments?
No. The published research was a feasibility and safety study in 60 patients, meant to show the approach is workable and reasonably safe, not a head-to-head comparison against other disc pain treatments.
What were the reported side effects?
The main safety issue noted was that in about 8 percent of patients, some of the injected gel shifted slightly beyond the disc space and caused increased pain or numbness, which required a follow-up procedure to remove the displaced material.
Should I ask my doctor about this treatment?
It is reasonable to mention any emerging option you have read about during a consult, but decisions about disc-related back pain should be based on an individual evaluation of your imaging, symptoms, and history, not on a single early-stage study.